Cancer Res Treat.  2025 Jan;57(1):83-94. 10.4143/crt.2024.073.

Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data

• Kim KY
• Kim HC
• Kim TJ
• Kim HK
• Moon MH
• Beck KS
• Suh YG
• Song CH
• Ahn JS
• Lee JE
• Jeon JH
• Jung CY
• Cho JS
• Choi YD
• Hwang SS
• Choi CM
• Jang SH
• Lim JU
• Korean Association for Lung Cancer, Korea Central Cancer Registry

• KMID: 2564583
• DOI: http://doi.org/10.4143/crt.2024.073

Abstract

Purpose
Recent development in perioperative treatment of resectable non–small cell lung cancer (NSCLC) have changed the landscape of early lung cancer management. The ADAURA trial has demonstrated the efficacy of adjuvant osimertinib treatment in resectable NSCLC patients; however, studies are required to show which subgroup of patients are at a high risk of relapse and require adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment. This study evaluated risk factors for postoperative relapse among patients who underwent complete resection.
Materials and Methods
Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.
Results
A total of 3,176 patients who underwent curative resection was evaluated. The mean observation time was approximately 35.4 months. Among stage I to IIIA NSCLC patients, the EGFR-mutant subgroup included 867 patients, and 75.2%, 11.2%, and 11.8% were classified as stage I, stage II, and stage III, respectively. Within the EGFR-mutant subgroup, 44 (5.1%) and 121 (14.0%) patients showed early and late recurrence, respectively. Multivariate analysis on association with postoperative relapse among the EGFR-mutant subgroup showed that age, pathologic N and TNM stages, pleural invasion status, and surgery type were independent significant factors.
Conclusion
Among the population that underwent complete resection for early NSCLC with EGFR mutation, patients with advanced stage, pleural invasion, or limited resection are more likely to show postoperative relapse.

Keyword

Recurrence; Non-small-cell lung carcinoma; ErbB receptors

Figure

• 

  Fig. 1. Study flow diagram. NSCLC, non–small cell lung cancer.

Reference

References

1. Muraoka Y, Yotsukura M, Yoshida Y, Nakagawa K, Shiraishi K, Kohno T, et al. Dynamics of recurrence after curative resection of nonsmall cell lung cancer. J Surg Oncol. 2023; 128:1205–12.

2. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario clinical practice guideline update. J Clin Oncol. 2017; 35:2960–74.

3. Choi J, Oh JY, Lee YS, Min KH, Shim JJ, Choi SI, et al. Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors. Korean J Intern Med. 2022; 37:127–36.

4. Kim MH, Kim SH, Lee MK, Eom JS. Recent advances in adjuvant therapy for non-small-cell lung cancer. Tuberc Respir Dis. 2024; 87:31–9.

5. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohe C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023; 389:137–47.

6. Lim JU. Update on adjuvant treatment in resectable non-small cell lung cancer and potential biomarkers predicting postoperative relapse. Tuberc Respir Dis. 2023; 86:14–22.

7. Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology: mainland China subset analysis of the PIONEER study. PLoS One. 2015; 10:e0143515.

8. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis. 2016; 79:58–69.

9. Sung MR, Tomasini P, Le LW, Kamel-Reid S, Tsao MS, Liu G, et al. Effects of ethnicity on outcomes of patients with EGFR mutation-positive NSCLC treated with EGFR tyrosine kinase inhibitors and surgical resection. JTO Clin Res Rep. 2022; 3:100259.

10. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019; 51:1400–10.

11. Travis WD, Brambilla E, Rami-Porta R, Vallieres E, Tsuboi M, Rusch V, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008; 3:1384–90.

12. Ni J, Guo T, Li Y, Yang X, Li Y, Zou L, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res. 2019; 8:967–78.

13. Isaka T, Ito H, Yokose T, Saito H, Adachi H, Murakami K, et al. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status. BMC Cancer. 2022; 22:966.

14. Yu Q, Du X, Fang Z, Mao X, Wu J, Wang B, et al. Predictive risk factors for early recurrence of stage pIIIA-N2 non-small cell lung cancer. Cancer Manag Res. 2021; 13:8651–61.

15. Shimizu K, Yoshida J, Nagai K, Nishimura M, Ishii G, Morishita Y, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 130:160–5.

16. Manac’h D, Riquet M, Medioni J, Le Pimpec-Barthes F, Dujon A, Danel C. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg. 2001; 71:1088–93.

17. Chen T, Luo J, Wang R, Gu H, Gu Y, Huang Q, et al. Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm. Oncotarget. 2017; 8:66576–83.

18. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378:113–25.

19. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947–57.

20. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020; 383:1711–23.

21. Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G. EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients. Cancer Manag Res. 2019; 11:1945–57.

22. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2:706–14.

23. Yoshida Y, Murayama T, Sato Y, Suzuki Y, Saito H, Nomura Y. Gender differences in long-term survival after surgery for non-small cell lung cancer. Thorac Cardiovasc Surg. 2016; 64:507–14.

24. Dolan D, Swanson SJ, Gill R, Lee DN, Mazzola E, Kucukak S, et al. Survival and recurrence following wedge resection versus lobectomy for early-stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2022; 34:712–23.

25. Shi Y, Wu S, Ma S, Lyu Y, Xu H, Deng L, et al. Comparison between wedge resection and lobectomy/segmentectomy for early-stage non-small cell lung cancer: a Bayesian meta-analysis and systematic review. Ann Surg Oncol. 2022; 29:1868–79.

26. Salati M, Brunelli A. Risk stratification in lung resection. Curr Surg Rep. 2016; 4:37.

27. Berry MF, Hanna J, Tong BC, Burfeind WR Jr, Harpole DH, D’Amico TA, et al. Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg. 2009; 88:1093–9.

28. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26:948–68.

29. Ferguson MK, Dignam JJ, Siddique J, Vigneswaran WT, Celauro AD. Diffusing capacity predicts long-term survival after lung resection for cancer. Eur J Cardiothorac Surg. 2012; 41:e81–6.

30. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017; 151:193–203.